Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599741 | 0.74 | GLRA3 (0.31) | — | |
| SCHEMBL31061862 | 0.73 | — | — | |
| SCHEMBL13283434 | 0.70 | — | — | |
| SCHEMBL11941344 | 0.70 | SMN1; SMN2 (0.33) | CA2LMNATP53NPC1RAB9A | |
| SCHEMBL1106198 | 0.70 | NPC1 (0.33) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5739987 | 0.68 | LMNA (0.48) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22140330 | 0.68 | NPC1 (0.36) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22140412 | 0.68 | NPC1 (0.32) | LMNATP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12601238 | 0.68 | ALDH1A1 (0.39) | CA1CA2LMNATP53ALOX15 | |
| SCHEMBL22140356 | 0.68 | NPC1 (0.32) | LMNATP53NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CA1 4571/4885CA2 3989/4885LMNA 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.